SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase IV (DPP-IV) inhibitors, and glucagon-like peptide-1 (GLP-1) analogs are T2DM medications with conflicting reports on skeletal muscle wasting [90,103].